Funding

Isomorphic Labs Raises $5B for AI Drug Design

November 18, 2026 · By Editorial Team

Isomorphic Labs Raises $5B for AI Drug Design

Isomorphic Labs, the drug-discovery company spun out of Google DeepMind in 2021, has raised $5 billion in a Series C round as it works to take its first AI-designed medicines into human trials. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor and Alphabet investing further. Every existing backer returned, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

The money will scale IsoDDE, the company’s drug-design engine, which uses simulation models across chemistry to design molecules, predict their properties and refine them before scientists choose candidates to make and test. Isomorphic reports positive preclinical results in its internal oncology and immunology programmes and in partnered work, but none of its candidates has entered a human trial yet, and it has named no date for the first one.

The round follows a $2.1 billion Series B in May, taking the company’s outside funding to about $7.7 billion in under two years. It did not disclose a valuation; reports had put the target at about $50 billion, but that figure was not confirmed. The round is also the first since founder and chief executive Demis Hassabis, who won the 2024 Nobel Prize in Chemistry for his AlphaFold work, stepped back from leading DeepMind to focus on drug discovery. The test now is clinical: turning promising preclinical results into medicines that work in people. Research teams weighing tools for this kind of work can compare the leading models in our Claude vs Gemini comparison, explore Gemini, or search the literature with Perplexity.

Source: TechCrunch and PR Newswire

Related stories